Key points are not available for this paper at this time.
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. (Funded by Medivation and Astellas Pharma; PREVAIL ClinicalTrials.gov number, NCT01212991.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Tomasz M. Beer
Andrew J. Armstrong
Dana E. Rathkopf
New England Journal of Medicine
University of Washington
Cornell University
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Beer et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69dd258403ecda3005e52d51 — DOI: https://doi.org/10.1056/nejmoa1405095